Business, energy, technology, markets and global industry news from Business News Today
Medical Devices & Diagnostics

Tissium targets the nerve repair market with $68 million and a sutureless FDA-authorised device

Tissium has secured approximately $68 million to expand the U.S. rollout of Coaptium Connect, a light-activated polymer system for peripheral nerve repair. Its commercial opportunity is significant, but surgeon adoption and stronger comparative evidence remain crucial.

Read More
Medical Devices & Diagnostics

Molecular Instruments targets a major multiplex IF bottleneck with automated HCR Gold IF on BOND RX

Discover how HCR Gold IF on BOND RX could streamline multiplex tissue research, preserve antibody workflows and reshape spatial biology.

Read More
Medical Devices & Diagnostics

What Imagion Biosystems’ AU$3.75m raise changes for the MagSense HER2 programme

Imagion Biosystems has converted FDA permission to proceed into funding for a Phase 1b/2 test of whether targeted MRI can improve HER2-positive breast cancer staging.

Read More
Pharma & Biotech

ProQR shows RNA editing works in humans, but can AX-0810 delay liver transplantation?

ProQR Therapeutics has produced the first human target-engagement evidence for its Axiomer RNA-editing platform. The results support its mechanism, but patient benefit, long-term safety and the choice between AX-0810 and AX-0811 remain unresolved.

Read More
Medical Devices & Diagnostics

How UpDoc’s clinical AI could transform insulin management without replacing physicians

UpDoc is moving patient-facing artificial intelligence beyond reminders and administrative support into insulin management. Its narrow FDA clearance, physician-defined limits and early clinical evidence reveal both the potential and the boundaries of autonomous chronic-disease care.

Read More
Medical Devices & Diagnostics

Can 5,000 Saber-C implantations turn Elevation Spine into a cervical fusion challenger?

Explore what Elevation Spine’s 5,000 Saber-C implants reveal about zero-profile cervical fusion adoption, evidence gaps and next steps.

Read More
Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

Read More
Medical Devices & Diagnostics

Butterfly Network’s Aleph Neuro partnership opens a new path for non-invasive brain imaging

Discover how Aleph Neuro’s brain images could reshape transcranial ultrasound and why clinical validation remains the next decisive test.

Read More
Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

NeuroSense Therapeutics says PrimeC produced biomarker changes consistent with its multi-target mechanism in an exploratory Alzheimer’s study, but an exceptionally small dataset leaves clinical efficacy, safety and commercial relevance unanswered.

Read More
Pharma & Biotech

MaaT Pharma seeks second review of MaaT013 as regulators question single-arm evidence

Discover why MaaT Pharma is challenging the negative CHMP opinion on MaaT013 and what the September review means for acute graft-versus-host disease.

Read More